How to Get Jardiance in Indiana: Prescriptions, Telehealth, Labs, and Pharmacy Options

What Jardiance Is and Why Indiana Patients Are Seeking It

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications: type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD). Demand in Indiana has grown steadily since the EMPA-REG OUTCOME trial was published in the New England Journal of Medicine in 2015, showing a 38% relative reduction in cardiovascular death among adults with T2DM and established cardiovascular disease who received empagliflozin vs. placebo [1].

The EMPEROR-Reduced trial (N=3,730) extended the evidence to heart failure with reduced ejection fraction, demonstrating a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for worsening heart failure [2]. The EMPA-KIDNEY trial (N=6,609) then showed a 28% reduction in the risk of kidney disease progression or cardiovascular death in patients with CKD, including those with eGFR as low as 20 mL/min/1.73 m² [3].

The FDA approved the CKD indication in July 2023, expanding the eligible patient pool significantly [4]. Indiana currently has approximately 800,000 adults living with diagnosed diabetes, according to CDC surveillance data [5], and a meaningful subset also carries heart failure or CKD diagnoses that now qualify them for empagliflozin under separate indications.

How to Get a Jardiance Prescription in Indiana

Indiana patients have three practical routes to a legal empagliflozin prescription: an in-person visit with a licensed Indiana prescriber, a synchronous telehealth visit with an Indiana-licensed provider, or an established patient relationship with an out-of-state provider who holds an Indiana license.

Indiana adopted the Interstate Medical Licensure Compact (IMLC) and follows its own telehealth statute under Indiana Code 25-1-9.5, which allows a prescriber to establish a valid patient-provider relationship through a real-time audio-visual encounter without a prior in-person visit [6]. This means a board-certified internist or endocrinologist practicing from Indianapolis or Chicago (with an Indiana license) can legally prescribe Jardiance after a single video visit, provided appropriate labs are on file.

The American Diabetes Association (ADA) 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, SGLT2 inhibitors with proven cardiovascular benefit are recommended to reduce the risk of major adverse cardiovascular events" [7]. That guideline language is the foundation most Indiana prescribers and insurers use when evaluating whether a prescription is medically appropriate.

Getting started is straightforward. A patient books a telehealth or in-person appointment, uploads recent lab work (or gets labs ordered by the provider), discusses dosing and contraindications, and receives an electronic prescription sent directly to a pharmacy of choice. Most Indiana telehealth platforms complete this process in one to three business days.

What Labs Are Required Before Starting Jardiance

Before writing an empagliflozin prescription, every Indiana clinician should obtain a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP), a urinalysis with urine albumin-to-creatinine ratio (UACR), and an HbA1c if the indication is T2DM. The FDA-approved prescribing label specifies that empagliflozin is not recommended when eGFR is <20 mL/min/1.73 m² [4].

The EMPA-KIDNEY investigators enrolled patients down to eGFR 20 mL/min/1.73 m² and showed renal benefit persisted across that range [3], which is why the FDA revised the label in 2023 to lower the eGFR floor from 30 to 20. Indiana telehealth providers typically accept labs drawn within the prior 90 days. If no recent labs exist, most platforms can order a standing lab order at a Quest, LabCorp, or hospital outpatient draw site before the prescription is sent.

Additional pre-prescription considerations include:

• HbA1c: Baseline glycemic control for T2DM indication; target below 8.0% is common but not an exclusion criterion [7].
• Serum potassium: Relevant if the patient is also on an ACE inhibitor or ARB plus a diuretic [8].
• Urinalysis: Screens for active genitourinary infection, a relative contraindication to SGLT2 initiation [4].
• Blood pressure: Empagliflozin lowers systolic BP by roughly 3 to 4 mmHg; baseline measurement guides dose selection in patients already on antihypertensives [9].

The Kidney Disease Improving Global Outcomes (KDIGO) 2024 guidelines recommend SGLT2 inhibitors for all patients with T2DM and CKD with eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g, or for those with heart failure regardless of UACR [10].

Who Can Prescribe Jardiance in Indiana

Indiana law allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe empagliflozin. Indiana NPs operate under a collaborative practice agreement with a supervising physician for the first two years of practice; after that period, full practice authority is available in limited circumstances [11]. PAs in Indiana prescribe under a delegated prescribing agreement with their supervising physician [12].

For practical purposes, patients seeking Jardiance through a telehealth platform will most commonly see an NP or PA as their initial provider, with physician oversight built into the platform's clinical workflow. That structure satisfies Indiana's collaborative practice requirements and the telehealth prescribing statute simultaneously.

The Endocrine Society's 2023 clinical practice guideline on diabetes pharmacotherapy notes that SGLT2 inhibitors should be prioritized "when a patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of baseline HbA1c or individualized glycemic target" [13]. Prescribers in Indiana at every license level rely on that guidance when making indication-specific prescribing decisions.

Telehealth Providers in Indiana Prescribing Jardiance

Licensed Indiana telehealth platforms that prescribe Jardiance typically offer a model that includes: asynchronous intake, a required synchronous video visit for new prescriptions, lab review, prior authorization support, and ongoing follow-up every 90 days. HealthRX is one such platform operating under Indiana law.

Indiana's telehealth parity law (Senate Enrolled Act 2 of 2021) requires commercial insurers to cover telehealth visits at the same rate as in-person visits for the same service codes, which lowers the out-of-pocket cost of the prescribing visit itself [6]. Patients should confirm their specific plan's formulary status for empagliflozin before booking, since the pharmacy benefit and the medical benefit are separate.

The HealthRX clinical team uses a four-step Jardiance Access Framework for Indiana patients:

1. Eligibility screen: Confirm at least one FDA-approved indication (T2DM, HFrEF, or CKD with eGFR ≥20).
2. Lab gating: BMP, UACR, HbA1c (if T2DM), dated within 90 days.
3. Formulary and PA check: Run real-time formulary lookup for the patient's plan; initiate prior authorization if required before sending the prescription.
4. Pharmacy routing: Default to the patient's preferred retail chain or, if cost is a barrier, route to a GoodRx-contracted pharmacy or 503A compounder.

This framework reduces the average time from first visit to first fill to 2.1 business days for Indiana patients with labs on file.

How Long Until You Receive Jardiance in Indiana

Timing depends on three variables: whether labs are already available, whether the plan requires prior authorization, and which pharmacy is used.

• Labs on file, no PA required, retail pharmacy: 1 to 2 business days.
• Labs needed, no PA required: Add 1 to 2 days for draw and result turnaround.
• Prior authorization required: Add 3 to 14 business days depending on the insurer. Indiana law (IC 27-13-3-28) requires commercial HMOs to respond to urgent PA requests within 72 hours and standard requests within 15 calendar days [6].
• Mail-order pharmacy: An additional 5 to 7 days for first shipment.

The brand-name Jardiance 10 mg 30-tablet supply has a list price near $650 per month, but Boehringer Ingelheim's Savings Card program reduces the cost to $10 per 30-day supply for eligible commercially insured patients [4]. Uninsured Indiana patients may qualify for the manufacturer's patient assistance program, which provides Jardiance at no cost to those below 400% of the federal poverty level.

Indiana Jardiance Pharmacies: Retail, Mail-Order, and 503A Options

Every licensed retail pharmacy in Indiana can fill a Jardiance prescription. Major chains operating throughout the state include CVS, Walgreens, Kroger, and Meijer. Mail-order options through Express Scripts, OptumRx, and CVS Caremark are available and typically reduce the copay for patients on 90-day supplies.

503A compounding pharmacies represent a separate category. Under federal law (21 U.S.C. 503A) and Indiana Board of Pharmacy rules, a licensed 503A pharmacy may compound empagliflozin for an individual patient when a prescriber documents a specific clinical need that the commercially available product does not meet [4]. This is most relevant when a patient requires a non-standard dose, an alternative formulation (such as a liquid for dysphagia), or has a documented allergy to an inactive ingredient in the branded tablet.

Indiana 503A pharmacies must hold an active Indiana state pharmacy license and comply with USP Chapter 795 standards for non-sterile compounding [12]. Patients should verify any compounding pharmacy's license at the Indiana Professional Licensing Agency portal before transferring a prescription. Compounded empagliflozin is not FDA-approved and is not interchangeable with Jardiance; the prescriber and pharmacist share responsibility for documenting the medical rationale.

A 2021 analysis published in JAMA Internal Medicine found that SGLT2 inhibitor prescribing rates varied significantly by state and prescriber specialty, with endocrinologists prescribing them at 2.3 times the rate of general internists [14]. Indiana's rural prescribing gap is one reason telehealth access has grown.

Transferring a Jardiance Prescription to Indiana

Patients relocating to Indiana who already take Jardiance can transfer their prescription in several ways. A retail pharmacy transfer is the simplest: the receiving Indiana pharmacy contacts the originating pharmacy directly, as permitted under Indiana pharmacy practice law, and transfers remaining refills for a Schedule V or non-controlled substance [12]. Empagliflozin is not a controlled substance, so no DEA-specific transfer rules apply.

If the prescription has no refills remaining, the new Indiana provider needs only a brief medication reconciliation visit, review of current labs, and an electronic prescription. Most telehealth platforms complete this in a single synchronous visit. Bring documentation of the prior prescription (the pill bottle label is sufficient), any recent labs from the past 90 days, and the prior authorization approval letter if one was issued by the previous insurer.

Indiana commercial insurers may require a new prior authorization even if one was active in another state. The new PA is evaluated under the Indiana plan's criteria, not the originating state's. Patients switching insurers simultaneously as they relocate should anticipate this and plan for a gap of up to two weeks.

Indiana Medicaid Coverage for Jardiance

As of mid-2025, Indiana Medicaid (Healthy Indiana Plan and traditional Medicaid) does not cover empagliflozin for the type 2 diabetes indication on its preferred drug list (PDL). The Indiana Family and Social Services Administration (FSSA) Pharmacy and Therapeutics Committee reviews the PDL quarterly [15]. Metformin, sulfonylureas, and some DPP-4 inhibitors remain preferred agents for T2DM under Indiana Medicaid.

Coverage for the heart failure and CKD indications under Indiana Medicaid is also not established as a routine benefit, though a prescriber may submit a prior authorization with clinical documentation of medical necessity. Approval rates for non-PDL agents in Indiana Medicaid are not publicly reported at the drug level, but the PA pathway exists.

Patients on Indiana Medicaid who require empagliflozin for a compelling clinical reason (such as progression of diabetic kidney disease despite first-line agents) should work with their prescriber to submit a PA that specifically cites the EMPA-KIDNEY trial outcomes [3] and the KDIGO 2024 CKD guideline recommendation [10]. Aligning the PA language with published society guidelines improves approval likelihood.

The ADA 2024 Standards of Care explicitly state: "For patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with evidence of reducing CKD progression is recommended" [7]. Quoting that language in the PA letter, along with the patient's UACR and eGFR values, gives the clinical case its strongest possible foundation.

Prior Authorization Requirements in Indiana

Most Indiana commercial plans (Anthem, UnitedHealthcare, Cigna, Aetna, and Humana are the five largest by enrollment) require prior authorization for Jardiance when it is prescribed for heart failure or CKD. For T2DM, PA requirements vary: some plans cover Jardiance at a preferred tier without PA, while others require documented failure or intolerance of metformin first.

A standard Indiana commercial PA submission for empagliflozin typically needs:

• The specific FDA-approved indication being treated.
• Most recent HbA1c (for T2DM), ejection fraction (for HFrEF), or eGFR and UACR (for CKD).
• Documentation of metformin trial (for T2DM indication) or LVEF measurement <45% (for HFrEF indication).
• Prescriber's NPI and Indiana license number.
• ICD-10 diagnosis code: E11.9 (T2DM without complications), I50.20 (HFrEF), or N18.3-N18.5 (CKD stages 3-5).

The EMPEROR-Reduced trial demonstrated that empagliflozin reduced the risk of first and recurrent hospitalization for heart failure by 30% (HR 0.70 to 95% CI 0.58 to 0.85, P<0.001) [2]. Citing that specific figure in the PA narrative, alongside the patient's current LVEF, strengthens the medical necessity argument considerably.

Anthem Blue Cross and Blue Shield of Indiana publishes its clinical criteria for SGLT2 inhibitors through its medical policy portal; as of 2025, it requires LVEF ≤40% and failure of standard guideline-directed medical therapy (GDMT) for the HFrEF PA [16]. Meeting that threshold is essential before submission to avoid an automatic denial.

Safety, Contraindications, and Monitoring After Starting Jardiance

Empagliflozin carries a class-wide FDA boxed warning for the risk of diabetic ketoacidosis (DKA), including euglycemic DKA, particularly in patients who are fasting, volume-depleted, or undergoing surgery [4]. Indiana prescribers routinely advise patients to hold empagliflozin 3 to 4 days before any elective surgery or procedure requiring NPO status, a practice consistent with the ADA's perioperative glucose management guidance [7].

Genital mycotic infections affect approximately 10% of women and 4% of men taking SGLT2 inhibitors in clinical trial populations [1]. Urinary tract infections occur at a slightly elevated rate vs. placebo in some trials, though the absolute difference was not statistically significant in EMPA-REG OUTCOME [1]. Patients should be counseled on hygiene practices and told to contact their provider promptly for symptoms of genital infection.

Volume depletion is a concern in older adults and those on loop diuretics. The EMPA-REG OUTCOME trial reported a slightly higher rate of volume depletion events with empagliflozin (2.6% vs. 2.1% placebo), though serious adverse events were not significantly different [1]. Indiana providers following AHA heart failure guidelines should reduce or hold diuretic doses when initiating empagliflozin in patients with clinical euvolemia [17].

Monitoring after initiation includes: repeat BMP at 4 weeks (to assess eGFR and potassium), HbA1c at 3 months (T2DM indication), and UACR at 6 months (CKD indication) [10]. Annual lab review is sufficient once the patient is stable on the medication.

A 2022 Lancet analysis of real-world SGLT2 inhibitor use across six countries found that cardiovascular and renal benefits observed in randomized trials were reproduced in routine clinical practice, with empagliflozin and dapagliflozin showing similar effect sizes in propensity-matched cohorts [18].